Latest News in the pharma Industry

Biopharma News

Seqirus to build $800m influenza vaccine manufacturing facility in Australia

Seqirus to build $800m influenza vaccine manufacturing facility in Australia

17 Nov 2020

The facility will be the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere.

Read more 
European Commission wraps up CureVac COVID-19 vaccine supply deal

European Commission wraps up CureVac COVID-19 vaccine supply deal

17 Nov 2020

Europeans set to benefit from the EC's authorization of COVID-19 candidate vaccine supply agreement, securing up to 405 million doses of CVnCoV

Read more 
Vibalogics establishes US presence with virotherapy facility in Boston

Vibalogics establishes US presence with virotherapy facility in Boston

16 Nov 2020

The specialist CDMO's $150 million 3-year investment plan will provide a complete suite of virotherapy services to support drug developers and their most "revolutionary" products.

Read more 
Pharmapack Podcast: The opportunities and challenges of bringing connected devices to market in the drug delivery sector

Pharmapack Podcast: The opportunities and challenges of bringing connected devices to market in the drug delivery sector

13 Nov 2020

Smart, connected devices are revolutionizing drug delivery in the ways they can gather, order and transmit crucial patient data to physicians

Read more 
Who are BioNTech?

Who are BioNTech?

12 Nov 2020

CPhI lifts the lid on the relatively little known German biotech and partner of Pfizer behind the most promising COVID19 vaccine candidate

Read more 
Biomanufacturing: a future shaped by evolving markets, technology and global events

Biomanufacturing: a future shaped by evolving markets, technology and global events

12 Nov 2020

Gareth Macdonald

The coronavirus pandemic has impacted biopharmaceutical manufacturing and is likely to continue to do so for years to come. But the pandemic is not the only thing changing how the industry goes about making medicines.

Read more 
Stelis starts next phase of investment into its biologics manufacturing facility

Stelis starts next phase of investment into its biologics manufacturing facility

11 Nov 2020

This phase sees the CDMO start work on installing two 2,000-L single-use bioreactor trains in its mammalian cGMP facility.

Read more 
Pfizer and BioNTech COVID vaccine proves 90% effective

Pfizer and BioNTech COVID vaccine proves 90% effective

10 Nov 2020

Results from a Phase III clinical study found Pfizer and BioNTech's mRNA-based vaccine candidate, BNT162b2, is more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection, the companies announced Monday...

Read more 
Altimmune signs up Lonza to manufacture intranasal COVID-19 vaccine

Altimmune signs up Lonza to manufacture intranasal COVID-19 vaccine

10 Nov 2020

Altimmune adds Lonza as a manufacturing partner for supply of AdCOVID, its single-dose intranasal vaccine candidate for COVID-19.

Read more 
It’s time for the pharmaceutical sector to do the smart thing

It’s time for the pharmaceutical sector to do the smart thing

10 Nov 2020

For many years, well before the arrival of COVID-19, the pharmaceutical sector has faced increasing pressures, with challenges such as fake goods and grey market diversion. There is also increased emphasis on how to ensure patient adherence, as this di...

Read more 
The challenges of innovating in packaging and drug delivery

The challenges of innovating in packaging and drug delivery

10 Nov 2020

In this interview with Pharmapack, Arnaud Steiner, R&D Packaging Manager at Virbac shares his thoughts on trending issues in the packaging market such as patient centricity and eco-design, the challenges of managing the development of new packaging and...

Read more 
Nostrum Laboratories recalls lots of metformin tablets after nitrosamine detection

Nostrum Laboratories recalls lots of metformin tablets after nitrosamine detection

4 Nov 2020

Company is the latest in a lengthening list of pharma companies recalling the diabetes medicine over unacceptable levels of NDMA

Read more